Intracytoplasmic sperm injection is still the best management of male factor infertility.

Competing Interests: Declaration of Interests P.X. has nothing to disclose. S.C. has nothing to disclose. O.K. has nothing to disclose. L.N. has nothing to disclose. A.D.J. has nothing to disclose. Z.R. has nothing to disclose. G.D.P. has nothing to disclose. R.J.A. reports research funding from Memphasys Ltd.; royalties from a book published with Cambridge University Press entitled “The Infertility Trap;” consult fees for CellOxess and Memphasys Ltd; honoraria for delivering Keynote Lectures to the Society for Free Radical Research (Christchurch, New Zealand), and the Organon SEED 2023 meeting (Sydney); travel support from CellOxess; We (Memphasys Ltd) have filed a provisional patent on a novel system for measuring antioxidant activity; Chair of the Hunter Branch of the Royal Society of New South Wales; hold stocks in a biotechnology company, Memphasys Ltd, which developed the electrophoretic sperm isolation system “Felix.” P.N.S. has nothing to disclose.